Global Pulmonary Arterial Hypertension (PAH) Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Drug
                       1.1.2 Regional Scope
                       1.1.3 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details Of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                           1.6.1.1 Approach 1: Commodity Flow Approach
                       1.6.2 Volume Price Analysis (Model 2)
                           1.6.2.1 Approach 2: Volume Price Analysis
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective - 1:
                       1.10.2 Objective - 2:
                       1.10.3 Objective - 3:
                       1.10.4 Objective - 4:
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
                   2.3 Competitive Insights
Chapter 3 Pulmonary Arterial Hypertension Market: Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent Market Outlook
                       3.1.2 Ancillary Market Outlook
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Product Pipeline Analysis, By Stage
                       3.3.1 Registration Phase
                   3.4 User Perspective Analysis
                       3.4.1 Consumer Behavior Analysis
                       3.4.2 Market Influencer Analysis
                   3.5 List Of Key End-Users, By Region / By Product / By Country
                   3.6 Regulatory Framework
                       3.6.1 Reimbursement framework
                           3.6.1.1 Therapy cost
                           3.6.1.2 Therapy monitoring cost
                           3.6.1.3 Average Selling Price
                       3.6.2 Standards & Compliances
                   3.7 Market Variable Analysis
                       3.7.1 Market Driver Analysis
                           3.7.1.1 Incidents of Pulmonary Arterial Hypertension (PAH)
                           3.7.1.2 Growing Geriatric Population
                           3.7.1.3 Government Support for Development of Orphan Drugs
                       3.7.2 Market Restraint Analysis
                           3.7.2.1 Patent Expiration Of Key Molecules
                       3.7.3 Industry Challenges
                   3.8 Pulmonary Arterial Hypertension Market: Analysis Tools
                       3.8.1 Porter’s Five Forces Analysis
                           3.8.1.1 Supplier Power: Low
                           3.8.1.2 Buyer Power: moderate
                           3.8.1.3 Substitution Threat: moderate
                           3.8.1.4 Threat from new entrant: moderate
                           3.8.1.5 Competitive rivalry: high
                       3.8.2 Pestel Analysis
                       3.8.3 Major Deals & Strategic Alliances Analysis
                       3.8.4 Market Entry Strategies
Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Segment Analysis
                   4.1 Pulmonary Arterial Hypertension Market: Definition & Scope
                   4.2 Pulmonary Arterial Hypertension: Market Share Analysis, 2018 & 2026
                   4.3 Prostacyclin and Prostacyclin Analogs
                       4.3.1 Prostacyclin and Prostacyclin Analogs market, 2015 - 2026 (USD Million)
                   4.4 Soluble Guanylate Cyclase (Sgc) Stimulators
                       4.4.1 Soluble Guanylate Cyclase (Sgc) Stimulators Market, 2015 - 2026 (USD Million)
                   4.5 Endothelin Receptor Antagonists (ERAs)
                       4.5.1 Endothelin Receptor Antagonists (Eras) Market, 2015 - 2026 (USD Million)
                   4.6 Phosphodiesterase 5 (Pde-5)
                       4.6.1 Phosphodiesterase 5 (Pde-5) Market, 2015 - 2026 (USD Million)
Chapter 5 Pulmonary Arterial Hypertension Market: Regional Analysis
                   5.1 Pulmonary Arterial Hypertension Market: Definition & Scope
                   5.2 Regional Market Snapshot
                   5.3 Regional Market Share and Leading Players, 2018
                       5.3.1 North America
                       5.3.2 Europe
                       5.3.3 Asia Pacific
                       5.3.4 Latin America
                       5.3.5 Middle East & Africa
                   5.4 Pulmonary Arterial Hypertension Market: Market Share Analysis, 2018 & 2026
                   5.5 North America
                       5.5.1 North America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.5.2 U.S.
                           5.5.2.1 U.S. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.5.3 Canada
                           5.5.3.1 Canada Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                   5.6 Europe
                       5.6.1 Europe Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.6.2 U.K.
                           5.6.2.1 U.K. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.6.3 Germany
                           5.6.3.1 Germany Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.6.4 France
                           5.6.4.1 France Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.6.5 Italy
                           5.6.5.1 Italy Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.6.6 Spain
                           5.6.6.1 Spain Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                   5.7 Asia Pacific
                       5.7.1 Asia Pacific Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.7.2 Japan
                           5.7.2.1 Japan Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.7.3 China
                           5.7.3.1 China Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.7.4 Australia
                           5.7.4.1 Australia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.7.5 South Korea
                           5.7.5.1 South Korea Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                   5.8 Latin America
                       5.8.1 Latin America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.8.2 Brazil
                           5.8.2.1 Brazil Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.8.3 Mexico
                           5.8.3.1 Mexico Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.8.4 Argentina
                           5.8.4.1 Argentina Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                   5.9 MEA
                       5.9.1 MEA Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.9.2 South Africa
                           5.9.2.1 South Africa Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.9.3 Saudi Arabia
                           5.9.3.1 Saudi Arabia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
                       5.9.4 UAE                      
                           5.9.4.1 UAE Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
Chapter 6 Company Profiles
                   6.1 Company Profiles
                       6.1.1 Actelion Pharmaceuticals, Ltd.
                           6.1.1.1 Company overview
                           6.1.1.2 Financial performance
                           6.1.1.3 Product benchmarking
                           6.1.1.4 Strategic initiatives
                       6.1.2 Gilead Sciences, Inc.
                           6.1.2.1 Company overview
                           6.1.2.2 Financial PErformance
                           6.1.2.3 Product benchmarking
                           6.1.2.4 Strategic initiatives
                       6.1.3 United Therapeutics Corporation
                           6.1.3.1 Company overview
                           6.1.3.2 Financial performance
                           6.1.3.3 PAH Global Sale
                           6.1.3.4 Product benchmarking
                           6.1.3.5 Strategic initiatives
                       6.1.4 Novartis International AG
                           6.1.4.1 Company overview
                           6.1.4.2 Financial Performance
                           6.1.4.3 Product benchmarking
                           6.1.4.4 Strategic initiatives
                       6.1.5 GlaxoSmithKline Plc. (GSK)
                           6.1.5.1 Company overview
                           6.1.5.2 Financial performance
                           6.1.5.3 Product benchmarking
                       6.1.6 Pfizer, Inc.
                           6.1.6.1 Company overview
                           6.1.6.2 Product benchmarking
                       6.1.7 Dong-A ST Co., Ltd.
                           6.1.7.1 Company overview
                           6.1.7.2 Financial performance
                           6.1.7.3 Product benchmarking
                           6.1.7.4 Strategic initiatives
                       6.1.8 Merck Sharp & Dohme Corp.
                           6.1.8.1 Company overview
                           6.1.8.2 Finanical Performance
                           6.1.8.3 Product benchmarking
                           6.1.8.4 Strategic initiatives
                       6.1.9 Bayer HealthCare
                           6.1.9.1 Company overview
                           6.1.9.2 Financial Performance
                           6.1.9.3 Product benchmarking
                           6.1.9.4 Strategic initiatives
                       6.1.10 Arena Pharmaceuticals
                           6.1.10.1 Company overview
                           6.1.10.2 Financial performance
                           6.1.10.3 Product benchmarking
Chapter 7 KOL Commentary
                   7.1 Key Insights
                   7.2 KOL Views
Chapter 8 Recommendations

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbrevations
Table 3 Product pipeline analysis
Table 4 Pipeline Analysis for the PAH Agents
Table 5 Monthly therapy cost for PAH agents
Table 6 Payer specific per patient per year monitoring cost by medication class
Table 7 Average selling prices for approved PAH agents in the U.S.
Table 8 Global Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 9 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 10 North America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 11 North America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 12 U.S. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 13 Canada Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 14 Europe Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 15 Europe Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 16 U.K. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 17 Germany Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 18 Spain Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 19 Italy Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 20 France Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 21 RoE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 22 Asia Pacific Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 23 Asia Pacific Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 24 Japan Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 25 China Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 26 India Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 27 Australia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 28 South Korea Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 29 RoAPAC Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 30 Latin America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 31 Latin America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 32 Brazil Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 33 Mexico Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 34 Argentina Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 35 RoLA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 36 MEA Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 37 MEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 38 South Africa Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 39 Saudi Arabia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 40 UAE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 41 RoMEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 Pulmonary arterial hypertension market snapshot (2018)
Fig. 11 Pulmonary arterial hypertension market segmentation
Fig. 12 Pulmonary arterial hypertension market: Strategy framework
Fig. 13 Market trends and outlook
Fig. 14 Parent market outlook
Fig. 15 Related/ancillary market outlook
Fig. 16 Penetration & growth prospect mapping
Fig. 17 Market driver relevance analysis (Current & future impact)
Fig. 18 Global prevalence of PAH
Fig. 19 Global geriatric population, 2014 - 2024 (Million)
Fig. 20 Market restraint relevance analysis (Current & future impact)
Fig. 21 Patent term expiry of the key PAH brand
Fig. 22 Porter’s five forces analysis
Fig. 23 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 24 Pulmonary arterial hypertension market drug class outlook: Segment dashboard
Fig. 25 Pulmonary arterial hypertension market: Drug class movement analysis
Fig. 26 Prostacyclin pathway
Fig. 27 Prostacyclin and prostacyclin analogs market, 2015 - 2026 (USD Million)
Fig. 28 Nitric oxide pathway
Fig. 29 Soluble guanylate cyclase (SGC) stimulators market, 2015 - 2026 (USD Million)
Fig. 30 Endothelial pathway
Fig. 31 Endothelin receptor antagonists (eras) market, 2015 - 2026 (USD Million)
Fig. 32 Nitric oxide pathway market, 2015 - 2026 (USD Million)
Fig. 33 Phosphodiesterase 5 (PDE-5) market, 2015 - 2026 (USD Million)
Fig. 34 Regional market place: Key takeaways
Fig. 35 Pulmonary Arterial Hypertension Market: Definition & Scope
Fig. 36 Regional Market Snapshot (Figures in USD Million, 2018)
Fig. 37 Regional Market Share, 2018 (USD Million)
Fig. 38 Regional outlook, 2018 & 2026
Fig. 39 North America market, 2015 - 2026 (USD Million)
Fig. 40 U.S. market, 2015 - 2026 (USD Million)
Fig. 41 Canada market, 2015 - 2026 (USD Million)
Fig. 42 Europe market, 2015 - 2026 (USD Million)
Fig. 43 U.K. market, 2015 - 2026 (USD Million)
Fig. 44 Germany market, 2015 - 2026 (USD Million)
Fig. 45 France market, 2015 - 2026 (USD Million)
Fig. 46 Italy market, 2015 - 2026 (USD Million)
Fig. 47 Spain market, 2015 - 2026 (USD Million)
Fig. 48 Asia Pacific market, 2015 - 2026 (USD Million)
Fig. 49 Japan market, 2015 - 2026 (USD Million)
Fig. 50 China market, 2015 - 2026 (USD Million)
Fig. 51 Australia market, 2015 - 2026 (USD Million)
Fig. 52 South Korea market, 2015 - 2026 (USD Million)
Fig. 53 Latin America market, 2015 - 2026 (USD Million)
Fig. 54 Brazil market, 2015 - 2026 (USD Million)
Fig. 55 Mexico market, 2015 - 2026 (USD Million)
Fig. 56 Argentina market, 2015 - 2026 (USD Million)
Fig. 57 MEA market, 2015 - 2026 (USD Million)
Fig. 58 South Africa market, 2015 - 2026 (USD Million)
Fig. 59 Saudi Arabia market, 2015 - 2026 (USD Million)
Fig. 60 UAE market, 2015 - 2026 (USD Million)